| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO | Director | President and CEO
2 companies
James Corbett last filed a Form 4 in June 2025, as President and CEO at ATEC. The filings on record cover 2 companies. James Corbett's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 77,082 shares of ATEC. Net of sales, the ATEC filings show accumulation of 34,000 shares.
James Corbett has 9 Form 4 filings on record from May 2015 to June 2025, across 2 companies: CEO at AVITA Medical (RCEL), 2021–2025; President and CEO at Alphatec (ATEC), 2015–2016.
The 12 reported transactions were 6 option or other derivative awards, 2 stock awards, 2 other transactions and 1 open-market sale, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $24K and 1 sale worth about $19K.
The only open-market purchase was 34,000 shares of ATEC at an average $0.71 on August 10, 2015, about $24K.
The only open-market sale was 1,445 shares of RCEL at an average $13.29 on December 26, 2023, about $19K. Twelve months later RCEL was down 4%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.